Member Info for LordSnooty

Nobody is in profit at $3.40 bar some directors with cheap shares from years ago. You have either to assume it's a distressed holder selling or it's part of a continuing effort to inject liquidity by said cheap holders offering up shares now for the sake of the future.

worth aiming for, then: $32.50. Sooner rather than later if you please, Mr Maguire.

I'm not that negative, but it will take time - one good licensing out will send the SP stratospheric.

Many of us did chuck some money at it. The only problem is that we did it five years too early.

http://c.eqcdn.com/_27934455e1caf3d38d7753e8e3ca1b10/xeneticbio/db/213/1091/pdf/Xenetic_Investor%20Presentation_12.2.2016.pdf

on the crushing of hope that the plunge in the SP has wrought since the beginning of the year - not a single live question asked in the CC by any of us loyal UK shareholders - nor by any new holders - and only one email addressed. As you say Boogies, let's hope yesterday's trading marks a turning point and that the Shire news supports a rise back to a more reasonable valuation.

Unless there's a regulatory announcement of news beforehand, there's not a chance Maguire will have anything new to say that is price sensitive during the CC. Most likely it will be the usual platitudes about building shareholder value blah blah. Meanwhile we have hit our all time low again today. I can't attend the CC live, but I hope to hear one or two UK shareholders giving the CEO a good roasting when I listen to the recording later on the website; share price performance has been pathetic, culminating in the Nov 7 giveaway IPO. Since then we have dropped a further fifteen percent and there is hardly a buyer in sight from day to day - to the extent that the CEO needs to explain why he thinks this is and what he's doing to address the problem. Someone kindly do old Snooty a favour and put Maguire on the spot please.

move to iWeb

I agree in part, Doze, but there's no doubt that these heavyweights add authority and gravitas to a company. Whether or not they will provide value for money to us shareholders in due course is an open question though.

He's clearly onboard for the Onco potential. Looks like the next raise will come sooner rather than later to pay for these big cheeses. I hope Scott has his sums right.

Parps - this is the kind of thing I like to read: ""A biotech like Advaxis (NASDAQ:ADXS) recently got a $30 million funding prior to reporting positive Phase 2 clinical trial results for cervical cancer. The biotech has a similar partnership [to that of XBIO] with a large biopharma and a orphan drug approval, yet the company has a market cap in excess of $300 million."

Clem - I agree some income in the short term would be the single most likely thing to put us back in the game. However, Maguire has been negotiating a deal to license EPO, our nearest-term possibility, for years now, and the trial process crawls slowly on. The signals from our business updates I interpret as implying a deal is still a long way off. On the other hand, with our big pharma tie-ups, there's little chance of us going bust or not being able to find finance somewhere. What is not clear, to me at least, is exactly why shares and warrants were given away so cheap for the IPO - was it, as I suggested, to pay back the subscribers for their financial support while we waited to get off OTC and onto NASDAQ? Or is our MCap, at $30m, really realistic compared to our peers? Take a look at this list from last July. Select some company tickers and compare our pipeline and stage of drug trial progress with others. Do our peers have a comparable MCap to ours? http://topforeignstocks.com/stock-lists/the-complete-list-of-biotech-stocks-trading-on-nasdaq/

Despite the PI-friendly attitude from the CEO over the years, I suspect that we're now just a bloody, stubborn nuisance to them, hanging on through thick and thin in the vain hope that one day they'll make some money and justify their salaries and lavish, self-awarded options. PR/IR has never been the slightest help either, so I don't expect anything there. I am pretty much resigned in the short and medium term to seeing the market makers push and shove a few shares here, a few shares there, up and down according to some arcane schedule unknown to us, and which we will never be privy to. Interspersed with that, we may get the odd F VIII milestone payment, the occasional P II EPO tenth cohort result. Meantime we grow older.

Did you ever receive a reply from Jenene Thomas? I had one last week which said, "We are planning on scheduling an investor update call in the coming weeks. We will keep you informed". Not that that helps our dismal situation in the slightest, I'm sure it will be full steam ahead with the usual clichés and platitudes and have zero effect on the share price.

Set the clock back to Year Zero - Ten cents old money and three years wasted.

5teve - I held these shares dormant in my iWeb account from the time we left AIM - they also wouldn't trade OTC. However, they always assured me that, once on NASDAQ, the stock would become tradeable and at regular US-trade prices. Last week, I spoke to iWeb and they raised my shares from the dead, just like Lazarus. I did a test buy, and lo! I am now the (rather disgusted at the price) possessor of another 25 shares at $3.9499, for a £5 commission plus the FX rate. So I can recommend iWeb (part of Lloyds/Halifax, I think) to anyone looking for a reasonable solution. As to whether anyone really wants to buy any more of these shares - clem is right when he says below that there may be some new investors coming fresh to this stock now we are on NASDAQ - but: we were stuck in the damn thing on OTCQB for nearly three years; the directors have been in a close period for a year so we have had no guidance for a long time; we are on NASDAQ but so far there is still no liquidity and hence no reasonable price discovery; and the SP has, in my opinion, been manipulated to suit certain, vested interests - e.g. the OPKO deal at ~$0.50 old money and the recent drop to $4.125 new money to give cheap IPO shares and warrants to, I suspect, reward existing IIs for their support while we struggled on OTC. At this price I think most of us will continue to hold for some recovery, but I don't know what news there can be in the short term that will aid such a recovery - perhaps some Shire (ex Baxter Factor VIII) milestone payments, some news on Virexxa, further cohort news on EPO? Who knows any more - we await an investor conference call, which I've been assured will take place once the close period is ended. Today's financials report may mark that point.

Please, Mr Scott, save us.

I tend to agree - we know that OPKO took some, and "other institutional investors" - exactly who, we don't yet know but sure to be insiders. If it wasn't clear while we were still on OTC that not only PIs but also the world-at-large is totally indifferent to XBIO, no matter whether the SP is $1 or $100, we are learning that now: there is no buying except for a few speculative tens or hundreds here, the odd five hundred there. On the sell side, the occasional PI dumps in frustration at the total lack of any sight of Maguire's enhancement of 'shareholder value'. It's unclear what will change this. We've been waiting for the famous 'inflection point', where we start to actually make money, for years. It seems as far away as ever. Bon weekend, tout le monde!

Can you be more opaque, Dozers?

A few weeks of this hundred shares here, seventy-seven shares there and they'll be kicked off this market anyway. Not sure what the point of being on NASDAQ is when they can sell a chunk of the Company privately at the equivalent of $0.49 ($16.17 after consolidation) to OPKO back in January, yet can only raise money from OPKO and others at $4.125 ($0.125 pre-consolidation) through the market in November.